Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674011 · ClinicalTrials.gov registry record
Hypertension in Breast Cancer Patients Receiving Bevacizumab
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- 10
- Enrollment target
NCT00674011 is a clinical trial that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants.
The verdict
NCT00674011 was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
This research study will look at the effect of an anti-angiogenesis medication called Bevacizumab on blood vessels. Anti-angiogenesis medicines fight cancer by cutting off a tumor's blood supply, starving the tumor of nutrients and oxygen. Previous studies have shown these types of drugs can cause hypertension. The purpose of this study is to help researchers better understand why these drugs cause hypertension. This information will assist researchers in learning how to control this side effect.
Interventions
- DRUG Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00674011
The ClinicalTrials.gov registry entry for NCT00674011 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab is the first listed.
NCT00674011 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00674011 about?
NCT00674011 is a clinical study titled "Hypertension in Breast Cancer Patients Receiving Bevacizumab". This research study will look at the effect of an anti-angiogenesis medication called Bevacizumab on blood vessels. Anti-angiogenesis medicines fight cancer by cutting off a tumor's blood supply, starving the tumor of nutrients and oxygen. Previous studies have shown these types of drugs can cause h...
What is the current status of trial NCT00674011?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2008-01. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00674011?
The interventions under investigation include: Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00674011?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.